BM8 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Biomarin Pharmaceutical Inc

Watchlist Manager

Watchlist

Price: 50.68 EUR

Market Cap: €9.3B

B	Biomarin Pharmaceutical Inc XBER:BM8	US
T	T-Mobile US Inc F:TM5	US
B	Bristol-Myers Squibb Co XBER:BRM	US
C	Canadian Imperial Bank of Commerce XBER:CAI	CA
R	Restaurant Brands International Inc LSE:0VFA	CA

Profitability Summary

Biomarin Pharmaceutical Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

80%

Strong 3Y Average Gross Margin

79%

Gross Margin is Increasing

77% > 80%

Low Operating Margin

10%

Sustainable 3Y Average Operating Margin

15%

Operating Margin is Increasing

3% > 10%

Low Net Margin

Sustainable 3Y Average Net Margin

11%

Net Margin is Increasing

3% > 8%

Exceptional Free Cash Flow Margin

23%

Strong 3Y Average Free Cash Flow Margin

14%

Free Cash Flow Margin is Increasing

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.